Celltrion Healthcare Co Ltd
KOSDAQ:091990
Gross Margin
Celltrion Healthcare Co Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW |
30%
|
|
| US |
|
Mckesson Corp
NYSE:MCK
|
87.4B USD |
4%
|
|
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
55.4B USD |
3%
|
|
| US |
|
Cencora Inc
NYSE:COR
|
55.1B USD |
3%
|
|
| US |
|
Cardinal Health Inc
NYSE:CAH
|
32.6B USD |
3%
|
|
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
34.6B AUD |
7%
|
|
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
65.6B CNY |
32%
|
|
| AU |
E
|
EBOS Group Ltd
OTC:EBOSY
|
8.2B USD |
13%
|
|
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.1B USD |
32%
|
|
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
53B CNY |
11%
|
|
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
55.4B HKD |
8%
|
Celltrion Healthcare Co Ltd
Glance View
Celltrion Healthcare Co Ltd has carved a distinctive niche in the competitive biotechnology landscape by capitalizing on its expertise in biosimilars, which are biopharmaceutical drugs almost identical to original products. The company's origins trace back to a broader vision of democratizing healthcare, striving to make biologic treatments more accessible and affordable worldwide. With its roots in South Korea, Celltrion Healthcare, a subsidiary of Celltrion Inc., has harnessed cutting-edge technology to replicate complex biological drugs. These drugs, usually utilized for chronic conditions such as autoimmune diseases and cancer, are pivotal in offering alternatives to high-cost branded biologics. By focusing on biosimilars, Celltrion addresses both a global healthcare cost crisis and a burgeoning demand for effective therapies as aging populations grow. The business model revolves around developing, manufacturing, and distributing these biosimilars. Celltrion Healthcare primarily benefits from the lower production costs compared to innovator biologics and the subsequent market penetration achieved through competitive pricing. They have established an extensive global distribution network, which enhances their reach. Collaborations with various international partners bolster their presence in strategic markets, allowing comprehensive coverage across multiple continents. Revenue is generated from licensing agreements, direct sales, and strategic partnerships, ensuring a diversified income stream. In parallel, the company's vigorous pipeline of new products promises sustained growth, aimed at expanding their therapeutic portfolio while leveraging their expertise to outpace competitors in this burgeoning field.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Celltrion Healthcare Co Ltd's most recent financial statements, the company has Gross Margin of 30%.
You don't have any saved screeners yet